City Of Santa Rosa

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years who have severe uncontrolled asthma. These children must be on medium to high doses of inhaled corticosteroids along with at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, double-blind, placebo-controlled study aims to better understand how tezepelumab affects asthma control in this pediatric population. Participants will be randomly assigned in a 2:1 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo for 52 weeks during the double-blind treatment period. Before this, there is a 4 to 6 week screening and run-in phase. After the treatment period, a 12-week follow-up phase occurs without treatment. Eligible participants can then join an optional open-label extension, receiving tezepelumab for an additional 104 weeks followed by another 12-week post-treatment follow-up. Throughout the study, participants will have regular assessments including lung function tests, asthma control questionnaires, and monitoring for asthma exacerbations. Researchers will measure the annualized rate of severe asthma flare-ups from the start of treatment to week 52. Safety and treatment adherence will also be closely monitored during all study phases, with total participation potentially extending over two years for those in the extension period.

Researchers are evaluating a single dose of rifaximin combined with loperamide compared to the current standard treatment of a single dose of azithromycin with loperamide for acute watery traveler's diarrhea. This phase 4 randomized controlled trial aims to compare the effectiveness of these two antibiotic treatments alongside loperamide in managing this condition. Participants are active duty military members aged 18 to 60 experiencing recent acute watery diarrhea that affects their daily activities or duties. Participants will be randomly assigned to one of two treatment groups: one group will receive a single oral dose of rifaximin 550 mg with loperamide 4 mg initially, followed by 2 mg of loperamide after each loose stool; the other group will receive a single oral dose of azithromycin 500 mg with the same loperamide dosing schedule. Loperamide use is limited to a maximum of 16 mg per day for two days. Both treatments involve a single antibiotic dose plus loperamide used as needed. During the study, participants will provide blood and stool samples at various times to assess infection and immune responses. They will complete a daily symptom diary and be monitored by the study doctor to track illness and recovery. Additionally, participants will complete a brief electronic questionnaire three months after treatment. The main outcome measured is the therapeutic effectiveness of the antibiotic and loperamide combination within one week of treatment.